The study will directly compare the two basal insulins in an exclusively once daily regimen. Outcomes measured in the study will include efficacy, effect on weight and hypoglycaemia in type 2 diabetes patients.
The efficacy study will involve more than 430 patients internationally, including 314 in the US. It follows the newly released positive outcomes from the Titrate study.
New data for Levemir will be presented at the 69th Annual Meeting on the American Diabetes Association. This will include results from the Predictive study, and data exploring the potential of Levemir use in children and adolescents.
Christoph Koenen, Corporate Vice President of Global Medical Affairs at Novo Nordisk, said: “This is the first study of its kind to directly compare once daily Levemir with insulin glargine, and the results will be important for both physicians and patients. It will help them to understand the comparative benefits of both insulins and choose the best treatment option.”